期刊文献+

呼吸训练对帕金森病患者肺功能和运动功能的效果 被引量:13

Effects of Respiratory Training on Pulmonary Function and Motor Function for Patients with Parkinson's Disease
下载PDF
导出
摘要 目的探讨呼吸训练对帕金森病患者肺功能和肢体运动功能的影响。方法2018年1月至2019年11月选取上海市第二康复医院原发性帕金森病住院患者60例,随机分为对照组(n=30)和观察组(n=30),两组均予常规康复,观察组采用Power Breathe训练系统予呼吸训练。治疗前和治疗4周后,测量患者肺功能,采用统一帕金森病评定量表(UPDRS)第Ⅱ、Ⅲ部分和改良Barthel指数(MBI)进行评定。结果治疗后,两组UPDRS第Ⅱ、Ⅲ部分和MBI评分均改善(|t|>2.550,P<0.05);观察组用力肺活量(FVC)、第一秒用力呼气容积(FEV1)、50%肺活量时的最大呼气流速(MEF50)明显升高(|t|>2.838,P<0.01),对照组无明显变化(|t|<1.058,P>0.05);与对照组相比,观察组FVC、FEV1、MEF50、MBI和UPDRS第Ⅱ部分评分均改善更多(|t|>2.191,P<0.05)。结论增加呼吸训练能显著改善帕金森病患者肺功能,从而提高患者的日常生活能力,但并不能进一步改善患者的运动功能。 Objective To explore the effects of respiratory training on pulmonary and motor function for patients with Parkinson's disease.Methods From January,2018 to November,2019,60 inpatients with idiopathic Parkinson's disease from the Second Rehabilitation Hospital of Shanghai were randomly divided into control group(n=30)and experimental group(n=30).All the patients accepted routine rehabilitation,while the experimental group accepted respiratory training with Power Breathe in addition.They were measured the pulmonary function,and assessed with Unified Parkinson's Disease Rating Scale(UPDRS)partⅡand III,and modified Barthel Index(MBI)before and four weeks after treatment.Results The scores of UPDRSⅡandⅢ,and MBI improved in both groups after treatment(|t|>2.550,P<0.05),while the forced vital capacity(FVC),forced expiratory volume in the first second(FEV1)and maximum expiratory flow rate at 50%vital capacity(MEF50)increased in the experimental group(|t|>2.838,P<0.01),but did not in the control group(|t|<1.058,P>0.05).FVC,FEV1,MEF50,MBI score and UPDRS II score improved more in the experimental group than in the control group(|t|>2.191,P<0.05).Conclusion Respiratory training can improve pulmonary function for patients with Parkinson's disease,to further improve their activities of daily living.No synergistic effect is found on motor function.
作者 厉坤鹏 周宗磊 张梓楠 施伯翰 陈浩 罗云 朱燕 LI Kun-peng;ZHOU Zong-lei;ZHANG Zi-nan;SHI Bo-han;CHEN Hao;LUO Yun;ZHU Yan(Department of Neurorehabilitation,the Second Rehabilitation Hospital of Shanghai,Shanghai 200441,China;West China School of Public Health and West China Fourth Hospital,Sichuan University,Chengdu,Sichuan 610041,China)
出处 《中国康复理论与实践》 CSCD 北大核心 2021年第3期320-324,共5页 Chinese Journal of Rehabilitation Theory and Practice
基金 上海市卫生和计划生育委员会科研课题计划面上项目(No.201740184) 上海市卫生和计划生育委员会科研课题计划青年项目(No.20184Y0179) 上海市宝山区科学技术委员会医学卫生项目(No.19-E-26)。
关键词 帕金森病 呼吸训练 肺功能 运动功能 Parkinson's disease respiratory training pulmonary function motor function
  • 相关文献

参考文献7

二级参考文献63

  • 1Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S,Jacobs AH, Rudolf J, Herholz K, Heiss WD. Nonlinearprogression of Parkinson disease as determined by serialpositron emission tomographic imaging of striatal fluorodopa FIB activity. Arch Neurol, 2005, 62:378-382.
  • 2Marques 0, Outeiro TF. Alpha - synuclein: from secretion todysfunction and death. Cell Death Dis, 2012, 3:E350.
  • 3Borghi R, Marchese R, Negro A, Marinelli L, Forloni G,Zaccheo D, Abbruzzese G, Tabaton M. Full length alpha -synuclein is present in cerebrospinal fluid from Parkinson'sdisease and normal subjects. Neurosci Lett, 2000,287:65-67.
  • 4Mollenhauer B, Locascio JJ, Schulz - Schaeffer W, Sixel - DoringF, Trenkwalder C, Schlossmacher MG. a - Synuclein and tauconcentrations in cerebrospinal fluid of patients presenting withparkinsonism: a cohort study. Lancet Neurol, 2011, 10:230-240.
  • 5Mollenhauer B, Trautmann E,Taylor P, Manninger P, Sixel -Doring F, Ebentheuer J, Trenkwalder C,Schlossmacher MG.Total CSF alpha - synuclein is lower in de novo Parkinsonpatients than in healthy subjects. Neurosci Lett, 2013, 532:44-48.
  • 6Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA,Kasai T, Ishigami N, Tamaoka A,Nakagawa M, El - Agnaf OM.Detection of elevated levels of a - synuclein oligomers in CSFfrom patients with Parkinson disease. Neurology, 2010,75:1766-1772.
  • 7Beach TG, Adler CH, Dugger BN, Serrano G, Hidalgo J,Henry-Watson J, Shill HA, Sue LI, Sabbagh MN, Akiyama H; ArizonaParkinson's Disease Consortium. Submandibular gland biopsyfor the diagnosis of Parkinson disease. J Neuropathol ExpNeurol, 2013, 72:130-136.
  • 8Adler CH, Dugger BN, Hinni ML, Lott DG, Driver-Dunckley E,Hidalgo J, Henry-Watson J, Serrano G, Sue LI, Nagel T, DuffyA, Shill HA, Akiyama H, Walker DG, Beach TG.Submandibular gland needle biopsy for the diagnosis ofParkinson disease. Neurology, 2014, 82:858-864.
  • 9Donadio V, Incensi A, Leta V, Giannoccaro MP, Scaglione C,Martinelli P, Capellari S, Avoni P, Baruzzi A, Liguori R. Skinnerve a - synuclein deposits: a biomarker for idiopathicParkinson disease. Neurology, 2014,82:1362-1369.
  • 10Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C,Goodlett DR, Wang Y, Armaly J, Tumas V, Zabetian CP,Leverenz JB, Shi M, Zhang J. Salivary a-synuclein and DJ-1:potential biomarkers for Parkinson、disease. Brain, 2011, 134:E178.

共引文献99

同被引文献174

引证文献13

二级引证文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部